Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial

Journal of Gastrointestinal Oncology

Milind Javle⁴  Wei Tan⁵  Alan Hutson⁵  Jinhee Yu³  Sidra Anwar²  Renuka Iyer¹ 

[1] Department of Internal Medicine, State University of New York, Buffalo NY, USADepartment of Internal Medicine, State University of New York, Buffalo NY, USADepartment of Internal Medicine, State University of New York, Buffalo NY, USA;Department of Biostatistics, State University of New York, Buffalo NY, USADepartment of Biostatistics, State University of New York, Buffalo NY, USADepartment of Biostatistics, State University of New York, Buffalo NY, USA;Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USADepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USADepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Centre, Houston TX, USA;Department of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USADepartment of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USADepartment of Biostatistics, Roswell Park Cancer Institute, Buffalo NY, USA

关键词: Quality of life (QoL);    pancreatic cancer;    biomarkers;    neoplasm;    European organization for research and treatment of cancer (EORTC);    palliative care;    supportive oncology;    outcomes;    pancreas;   

DOI  :  10.3978/j.issn.2078-6891.2014.070

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown